Search Results
Search for other papers by Margarida M Moura in
Google Scholar
PubMed
Search for other papers by Branca M Cavaco in
Google Scholar
PubMed
Unidade de Investigação em Patobiologia Molecular (UIPM), Serviço de Endocrinologia, Clínica Universitária de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
Unidade de Investigação em Patobiologia Molecular (UIPM), Serviço de Endocrinologia, Clínica Universitária de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
mutated (total mutated samples/total samples tested) for that particular tumor type. RAS mutations have also been detected in medullary thyroid carcinomas (MTCs), and this subject will be further discussed in section ‘ RAS mutations in MTC
Search for other papers by Libero Santarpia in
Google Scholar
PubMed
Search for other papers by George A Calin in
Google Scholar
PubMed
Search for other papers by Liana Adam in
Google Scholar
PubMed
Search for other papers by Lei Ye in
Google Scholar
PubMed
Search for other papers by Alfredo Fusco in
Google Scholar
PubMed
Search for other papers by Serena Giunti in
Google Scholar
PubMed
Search for other papers by Christina Thaller in
Google Scholar
PubMed
Search for other papers by Laura Paladini in
Google Scholar
PubMed
Search for other papers by Xinna Zhang in
Google Scholar
PubMed
Search for other papers by Camilo Jimenez in
Google Scholar
PubMed
Search for other papers by Francesco Trimarchi in
Google Scholar
PubMed
Search for other papers by Adel K El-Naggar in
Google Scholar
PubMed
Departments of Endocrine Neoplasia and Hormonal Disorders, Experimental Therapeutics , Urology, Department of Oncology, Department of Pathology, Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Department of Oncology, Department of Gynecologic Oncology, Department of Endocrinology, Department of Pathology, Department of Internal Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Search for other papers by Robert F Gagel in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour thought to originate from neural crest parafollicular C-cells. Approximately 25% of MTC cases occur in the context of autosomal dominant multiple endocrine neoplasia syndrome
Search for other papers by Teresa Ramone in
Google Scholar
PubMed
Search for other papers by Cristina Romei in
Google Scholar
PubMed
Search for other papers by Raffaele Ciampi in
Google Scholar
PubMed
Search for other papers by Roberta Casalini in
Google Scholar
PubMed
Search for other papers by Angelo Valetto in
Google Scholar
PubMed
Search for other papers by Veronica Bertini in
Google Scholar
PubMed
Search for other papers by Francesco Raimondi in
Google Scholar
PubMed
Search for other papers by Anthony Onoja in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
from follicular cells, while medullary thyroid carcinoma (MTC) is derived from parafollicular C cells. SCNAs were identified in 27.2% of papillary thyroid carcinomas ( Cancer Genome Atlas Research Network et al. 2014 ), while in MTC, a variable
Search for other papers by Marta Kaczmarek-Ryś in
Google Scholar
PubMed
Search for other papers by Katarzyna Ziemnicka in
Google Scholar
PubMed
Department of General, Endocrinological Surgery and Gastroenterological Oncology, Poznan University of Medical Sciences, Poznań
Search for other papers by Andrzej Pławski in
Google Scholar
PubMed
Search for other papers by Bartłomiej Budny in
Google Scholar
PubMed
Search for other papers by Michał Michalak in
Google Scholar
PubMed
Search for other papers by Szymon Hryhorowicz in
Google Scholar
PubMed
Search for other papers by Justyna Hoppe-Gołębiewska in
Google Scholar
PubMed
Search for other papers by Paweł Boruń in
Google Scholar
PubMed
Search for other papers by Monika Gołąb in
Google Scholar
PubMed
Search for other papers by Małgorzata Czetwertyńska in
Google Scholar
PubMed
Search for other papers by Maria Sromek in
Google Scholar
PubMed
Search for other papers by Marlena Szalata in
Google Scholar
PubMed
Search for other papers by Marek Ruchała in
Google Scholar
PubMed
Department of Biochemistry and Biotechnology, Poznan University of Life Sciences, Poznan, Poland
Search for other papers by Ryszard Słomski in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) occurs sporadically (sMTC) or as an inherited cancer (hMTC). The hereditary form may be present as a component of the multiple endocrine neoplasia type 2 syndrome (MEN2) or as an isolated MTC
Search for other papers by Zixia Tao in
Google Scholar
PubMed
Search for other papers by Xianzhao Deng in
Google Scholar
PubMed
Search for other papers by Bomin Guo in
Google Scholar
PubMed
Search for other papers by Zheng Ding in
Google Scholar
PubMed
Search for other papers by Youben Fan in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) originates from parafollicular cells of the thyroid and is characterized by the secretion of calcitonin and carcinoembryonic antigen. Unlike differentiated thyroid carcinoma, endocrine suppressive
Search for other papers by Rodrigo A Toledo in
Google Scholar
PubMed
Search for other papers by Roxanne Hatakana in
Google Scholar
PubMed
Search for other papers by Delmar M Lourenço Jr in
Google Scholar
PubMed
Search for other papers by Susan C Lindsey in
Google Scholar
PubMed
Search for other papers by Cleber P Camacho in
Google Scholar
PubMed
Search for other papers by Marcio Almeida in
Google Scholar
PubMed
Search for other papers by José V Lima Jr in
Google Scholar
PubMed
Search for other papers by Tomoko Sekiya in
Google Scholar
PubMed
Search for other papers by Elena Garralda in
Google Scholar
PubMed
Search for other papers by Michel S Naslavsky in
Google Scholar
PubMed
Search for other papers by Guilherme L Yamamoto in
Google Scholar
PubMed
Search for other papers by Monize Lazar in
Google Scholar
PubMed
Search for other papers by Osorio Meirelles in
Google Scholar
PubMed
Search for other papers by Tiago J P Sobreira in
Google Scholar
PubMed
Search for other papers by Maria Lucia Lebrao in
Google Scholar
PubMed
Search for other papers by Yeda A O Duarte in
Google Scholar
PubMed
Search for other papers by John Blangero in
Google Scholar
PubMed
Search for other papers by Mayana Zatz in
Google Scholar
PubMed
Search for other papers by Janete M Cerutti in
Google Scholar
PubMed
Search for other papers by Rui M B Maciel in
Google Scholar
PubMed
Endocrine Genetics Unit (Laboratório de Investigação Médica/LIM-25) of Hospital das Clínicas, Nursing School, School of Public Health, Human Genome Research Center, Division of Genetics, Division of Endocrinology, Brazilian National Laboratory of Biosciences, Centro Integral Oncológico Clara Campal, Department of Genetics, Endocrinology Division, Laboratory of Epidemiology and Population Sciences, University of São Paulo School of Medicine, São Paulo, São Paulo 05403-010, Brazil
Search for other papers by Sergio P A Toledo in
Google Scholar
PubMed
Introduction MEN2 (MIM #164761) is a dominantly inherited multiglandular tumour syndrome that presents with a high penetrance of medullary thyroid carcinoma (MTC; observed in virtually 100% of cases), phaeochromocytoma (50%) and parathyroid adenoma
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Pathology Department, Histopathology Core Unit, Endocrinology Division, Endocrinology Service, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Search for other papers by Cristina Rodríguez-Antona in
Google Scholar
PubMed
Search for other papers by Iván Muñoz-Repeto in
Google Scholar
PubMed
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Pathology Department, Histopathology Core Unit, Endocrinology Division, Endocrinology Service, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Search for other papers by Lucia Inglada-Pérez in
Google Scholar
PubMed
Search for other papers by Aguirre A de Cubas in
Google Scholar
PubMed
Search for other papers by Veronika Mancikova in
Google Scholar
PubMed
Search for other papers by Marta Cañamero in
Google Scholar
PubMed
Search for other papers by Agnieszka Maliszewska in
Google Scholar
PubMed
Search for other papers by Álvaro Gómez in
Google Scholar
PubMed
Search for other papers by Rocío Letón in
Google Scholar
PubMed
Search for other papers by Luis J Leandro-García in
Google Scholar
PubMed
Search for other papers by Iñaki Comino-Méndez in
Google Scholar
PubMed
Search for other papers by Lara Sanchez in
Google Scholar
PubMed
Search for other papers by Cristina Álvarez-Escolá in
Google Scholar
PubMed
Search for other papers by Javier Aller in
Google Scholar
PubMed
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Pathology Department, Histopathology Core Unit, Endocrinology Division, Endocrinology Service, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Search for other papers by Alberto Cascón in
Google Scholar
PubMed
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Pathology Department, Histopathology Core Unit, Endocrinology Division, Endocrinology Service, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) arises from the parafollicular cells of the thyroid gland. Sporadic MTC accounts for 75% of the cases, and the remaining 25% is inherited in nature as part of multiple endocrine neoplasia type 2
Department of Nuclear Medicine and Thyroid Centre, Section of Endocrinology and Diabetology, Nuclear Medicine, Endocrine Unit, Oncology Institute of Southern Switzerland, Bellinzona, 6500, Switzerland
Search for other papers by Pierpaolo Trimboli in
Google Scholar
PubMed
Search for other papers by Ettore Seregni in
Google Scholar
PubMed
Search for other papers by Giorgio Treglia in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
Search for other papers by Luca Giovanella in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) is a malignancy that originates from thyroid parafollicular C cells and accounts for about 5% of thyroid cancers ( Kloos et al . 2009 ). In the majority of cases (i.e., four out of every five), this
Search for other papers by Lucieli Ceolin in
Google Scholar
PubMed
Search for other papers by Marta Amaro da Silveira Duval in
Google Scholar
PubMed
Search for other papers by Antônio Felippe Benini in
Google Scholar
PubMed
Search for other papers by Carla Vaz Ferreira in
Google Scholar
PubMed
Search for other papers by Ana Luiza Maia in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) is a malignant tumor originating in parafollicular or C cells of the thyroid. The main secretory product of MTC is calcitonin, a specific and highly sensitive biomarker that is produced by normal
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Aimee R Hayes in
Google Scholar
PubMed
Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed
Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed
Green Templeton College, University of Oxford, Oxford, UK
Centre for Endocrinology, Barts and the London School of Medicine, London, UK
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Introduction Medullary thyroid carcinoma (MTC) is a malignant neuroendocrine tumour originating from the parafollicular or C-cells of the thyroid, capable of secreting calcitonin and carcinoembryonic antigen (CEA) ( Ceolin et al. 2019 ). It